Versant Capital Management, Inc Halozyme Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $454 Million
- Q4 2024
A detailed history of Versant Capital Management, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 438 shares of HALO stock, worth $24,427. This represents 0.0% of its overall portfolio holdings.
Number of Shares
438
Previous 21
1985.71%
Holding current value
$24,427
Previous $1,000
1900.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
539Shares Held
126MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$983 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$719 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$370 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$227 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$190 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.77B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...